Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACRS NASDAQ:CADL NASDAQ:DSGN NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.23-4.6%$4.91$1.46▼$5.88$730.44M0.762.04 million shs760,681 shsCADLCandel Therapeutics$9.56-3.0%$9.01$4.35▼$11.36$700.46M-0.521.56 million shs1.01 million shsDSGNDesign Therapeutics$11.78+1.3%$12.33$3.76▼$17.25$735.74M1.58886,532 shs417,080 shsIMUXImmunic$13.39-6.2%$14.13$5.06▼$15.84$182.39M1.37163,927 shs155,709 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-7.92%+6.52%+21.49%+211.31%CADLCandel Therapeutics0.00%-6.09%+0.95%+47.08%+37.36%DSGNDesign Therapeutics0.00%-6.28%-12.35%-5.99%+175.88%IMUXImmunic0.00%-11.68%-11.15%+52.14%+34.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACRSAclaris Therapeutics$5.23-4.6%$4.91$1.46▼$5.88$730.44M0.762.04 million shs760,681 shsCADLCandel Therapeutics$9.56-3.0%$9.01$4.35▼$11.36$700.46M-0.521.56 million shs1.01 million shsDSGNDesign Therapeutics$11.78+1.3%$12.33$3.76▼$17.25$735.74M1.58886,532 shs417,080 shsIMUXImmunic$13.39-6.2%$14.13$5.06▼$15.84$182.39M1.37163,927 shs155,709 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACRSAclaris Therapeutics0.00%-7.92%+6.52%+21.49%+211.31%CADLCandel Therapeutics0.00%-6.09%+0.95%+47.08%+37.36%DSGNDesign Therapeutics0.00%-6.28%-12.35%-5.99%+175.88%IMUXImmunic0.00%-11.68%-11.15%+52.14%+34.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACRSAclaris Therapeutics 3.13Buy$11.50119.89% UpsideCADLCandel Therapeutics 2.60Moderate Buy$18.5794.26% UpsideDSGNDesign Therapeutics 2.88Moderate Buy$16.5040.07% UpsideIMUXImmunic 3.00Buy$47.57255.28% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, ACRS, DSGN, and CADL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026DSGNDesign Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026CADLCandel Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$22.006/24/2026ACRSAclaris Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/2/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$13.006/1/2026ACRSAclaris Therapeutics Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/29/2026IMUXImmunic Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/22/2026IMUXImmunic Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform5/22/2026IMUXImmunic B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$40.00 ➝ $27.005/15/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/14/2026IMUXImmunic Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$19.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACRSAclaris Therapeutics$7.83M93.29N/AN/A$0.85 per share6.15CADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ADSGNDesign TherapeuticsN/AN/AN/AN/A$3.73 per shareN/AIMUXImmunicN/AN/AN/AN/A($0.55) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACRSAclaris Therapeutics-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.98N/AN/AN/AN/A-60.42%-41.33%8/13/2026 (Estimated)DSGNDesign Therapeutics-$69.79M-$1.20N/AN/AN/AN/A-33.07%-31.29%8/6/2026 (Estimated)IMUXImmunic-$97.17M-$5.58N/AN/AN/AN/A-220.75%-132.04%8/6/2026 (Estimated)Latest IMUX, ACRS, DSGN, and CADL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026CADLCandel Therapeutics-$0.22N/AN/AN/AN/AN/A8/6/2026Q2 2026ACRSAclaris Therapeutics-$0.16N/AN/AN/A$1.38 millionN/A8/6/2026Q2 2026DSGNDesign Therapeutics-$0.36N/AN/AN/AN/AN/A8/6/2026Q2 2026IMUXImmunic-$1.1756N/AN/AN/AN/AN/A5/14/2026Q1 2026CADLCandel Therapeutics-$0.2958-$0.14+$0.1558-$0.14N/AN/A5/13/2026Q1 2026IMUXImmunic-$0.71-$1.08-$0.37-$1.08N/AN/A5/7/2026Q1 2026ACRSAclaris Therapeutics-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million4/28/2026Q1 2026DSGNDesign Therapeutics-$0.36-$0.29+$0.07-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACRSAclaris TherapeuticsN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/ADSGNDesign TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACRSAclaris TherapeuticsN/A4.034.03CADLCandel Therapeutics0.3428.0528.05DSGNDesign TherapeuticsN/A22.2822.28IMUXImmunicN/A4.924.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACRSAclaris Therapeutics98.34%CADLCandel Therapeutics13.93%DSGNDesign Therapeutics56.64%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipACRSAclaris Therapeutics4.80%CADLCandel Therapeutics14.30%DSGNDesign Therapeutics17.10%IMUXImmunic5.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACRSAclaris Therapeutics100139.66 million132.96 millionOptionableCADLCandel Therapeutics6073.27 million62.79 millionOptionableDSGNDesign Therapeutics4062.46 million51.78 millionOptionableIMUXImmunic7013.62 million12.87 millionOptionableIMUX, ACRS, DSGN, and CADL HeadlinesRecent News About These CompaniesImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from AnalystsJuly 26 at 4:28 AM | marketbeat.comImmunic to Participate in Investor Conferences in JulyJuly 9, 2026 | prnewswire.comImmunic Expands Equity Plan and Reelects Board DirectorsJune 29, 2026 | tipranks.comImmunic Adds Veteran Biopharma Leader to BoardJune 25, 2026 | theglobeandmail.comImmunic to Participate in Investor, Industry and Scientific Conferences in JuneJune 10, 2026 | prnewswire.comImmunic presents new vidofludimus calcium data at multiple sclerosis conferenceMay 28, 2026 | proactiveinvestors.comImmunic Highlights Positive Phase 2 CALLIPER MS DataMay 28, 2026 | tipranks.comImmunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple SclerosisMay 28, 2026 | prnewswire.comImmunic names Erik Lundgren as CEO as it advances Phase 3 MS trialsMay 27, 2026 | proactiveinvestors.comImmunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive OfficerMay 27, 2026 | prnewswire.comImmunic appoints Biogen, Cubist veteran Mike Bonney as board chair ahead of key MS trial readoutMay 19, 2026 | proactiveinvestors.comAnalysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Immunic (IMUX)May 19, 2026 | theglobeandmail.comImmunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of DirectorsMay 19, 2026 | prnewswire.comImmunic (IMUX) Gets a Buy from LifeSci CapitalMay 18, 2026 | theglobeandmail.comIs Immunic (NASDAQ:IMUX) In A Good Position To Deliver On Growth Plans?May 17, 2026 | finance.yahoo.comImmunic advances Phase 3 MS program, eyes topline data by year-endMay 13, 2026 | proactiveinvestors.comImmunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | prnewswire.comImmunic: Saved By A 200 Million Private PlacementMay 12, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Hinge Health, Inc. Class A (HNGE)May 8, 2026 | theglobeandmail.comImmunic to Participate in Investor and Medical Conferences in MayApril 30, 2026 | prnewswire.comImmunic Appoints Veteran Neurology Leader as Chief Medical OfficerApril 30, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, ACRS, DSGN, and CADL Company DescriptionsAclaris Therapeutics NASDAQ:ACRS$5.23 -0.25 (-4.56%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.26 +0.03 (+0.67%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Candel Therapeutics NASDAQ:CADL$9.56 -0.30 (-3.04%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$9.55 -0.01 (-0.10%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Design Therapeutics NASDAQ:DSGN$11.78 +0.15 (+1.29%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$11.77 -0.01 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Immunic NASDAQ:IMUX$13.39 -0.89 (-6.23%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$13.34 -0.05 (-0.41%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
